Frances (Blevins) Arters, PA-C, MMSc
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MMS/MMSc, Tufts University School of Medicine
BS, Suffolk University
Websites
favorite icon BUMC




Frances (Blevins) Arters, PA-C, is a board-certified Physician Assistant. She joined the Center for Hematology and Medical Oncology at Boston Medical Center (BMC) in 2015 and works with the hematology team. She is an Assistant Professor at Boston University (BU) School of Medicine and a preceptor for students from BU’s Physician Assistant Program.

PA Arters graduated from the Tufts University School of Medicine Physician Assistant program, from which she obtained her Master of Medical Science degree. She works in both malignant and benign hematology and is a member of national organizations including the American Society of Hematology (ASH), Advanced Practitioner Society for Hematology and Oncology and American Academy of Physician Assistants.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Fraser CS, Spetz JKE, Qin X, Presser A, Choiniere J, Li C, Yu S, Blevins F, Hata AN, Miller JW, Bradshaw GA, Kalocsay M, Sanchorawala V, Sarosiek S, Sarosiek KA. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022 Oct 02; 13(1):5789. PMID: 36184661; PMCID: PMC9527241; DOI: 10.1038/s41467-022-33461-z;
     
  2. Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568.View Related Profiles. PMID: 35367193
     
  3. Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644.View Related Profiles. PMID: 35227897; DOI: 10.1016/j.critrevonc.2022.103644;
     
  4. Hughes DM, Toste C, Nelson C, Escalon J, Blevins F, Shah B. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series. J Adv Pract Oncol. 2021 Jul; 12(5):508-517.View Related Profiles. PMID: 34430061; PMCID: PMC8299792; DOI: 10.6004/jadpro.2021.12.5.6;
     
  5. Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 05 27; 137(21):2987-2989.View Related Profiles. PMID: 33728443
     
  6. Hughes D, Jhaveri R, Shah B, Blevins F, Rodriguez, A, Sarosiek S, Lerner A, Sloan JM, Sanchorawala V. Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis. Blood. 2020. View Publication
  7. Hughes D, Blevins F, Shah B, Sarosiek S, Lerner A, Sloan JM. Blood. Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center. ASH Publications. 2019. View Publication

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 7 publications over 4 distinct years, with a maximum of 3 publications in 2022

YearPublications
20191
20201
20212
20223

Contact for Mentoring:

818 Harrison Ave
Boston MA 02118
Google Map


Arters's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department